Charles Hudson
Dermatology · Evansville, INNPI 1356393102
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,700 of the $91,623 with a category attached, or 80.4%. AbbVie accounts for 85.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $52,625 and has fallen 99.6% since, to $198 in 2025. Among dermatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $327.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$78K
- VYNE Pharmaceuticals Inc.$9K
- Merz North America, Inc.$1K
- Almirall LLC$800
- Lilly USA, LLC$463
- Novartis$362
- plus $2K from 18 others
Across 365 payments — averaging $1374.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$195K
- Dermavant Sciences, Inc.$81K
- Bausch Health US, LLC$65K
- Galderma Research & Development, LLC$63K
- Regeneron$62K
- Pfizer$36K
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$73,70080%
- Travel & lodging$9,78911%
- Food & beverage$7,2418%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $77,850 |
| VYNE Pharmaceuticals Inc. | 13 | $8,694 |
| Merz North America, Inc. | 18 | $1,146 |
| Almirall LLC | 1 | $800 |
| Lilly USA, LLC | 14 | $463 |
| Novartis | 11 | $362 |
| Sun Pharmaceutical Industries Inc. | 8 | $342 |
| Johnson & Johnson | 16 | $237 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $210 |
| EPI Health, LLC | 12 | $204 |
| LEO Pharma Inc. | 11 | $202 |
| UCB, Inc. | 3 | $193 |
| Galderma Laboratories, L.p. | 3 | $178 |
| Pfizer | 4 | $176 |
| Regeneron Healthcare Solutions, Inc. | 3 | $165 |
| Dermira, Inc. | 1 | $101 |
| Journey Medical Corporation | 3 | $77 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Dermavant Sciences, Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Prugen, Inc. Pharmaceuticals | 2 | $19 |
| Boston Scientific | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Encore Dermatology Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$91,623 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 15 | $66,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $6,980 |
| ValacyclovirValacyclovir Hcl | 33 | $651 |
| Minocycline Hcl | 24 | $270 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $47 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Evansville
- Thomas SelbyEvansville$15K
- Celine MestelEvansville$11K
- Jamie MullEvansville$10K
- Karl StaserEvansville$9K
- Dylan GreeneyEvansville$8K
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.